Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.
Erysol gel 25g (February 23, 2012)
- Starting date:
- February 23, 2012
- Posting date:
- March 19, 2012
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type II
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-2012A35
Reason
Erysol Gel 25g have been found to have concentrations of erythromycin that either do not or may not support the label claim and expiry dating on the product. Product will be discontinued.
Depth of distribution
Wholesalers and pharmacies
Affected products
Erysol gel 25g
DIN, NPN, DIN-HIM
DIN 02034506
Dosage form
Topical Gel
Strength
- Erythromycin 2%w/w
- Ethyl alcohol 75% w/w
- Octinoxate 7.5% w/w
- Avobenzone 2% w/w
Lot or serial number
H1191, H0741, H1011, H1921, H2601, J0362, J1343, J2442, J2442-B, K1741, L0241
Companies
- Recalling Firm
- GlaxoSmithKline Inc.
7333 Mississauga Rd
Mississauga Ontario
Canada L5N 6L4
- Marketing Authorization Holder
- Therapex,
Division of DE E-Z-EM Canada Inc.
11065 L.-H. Lafontaine Blvd. Quebec
Canada H1J 2Z4
- Date modified: